JANNETTE VILLAFRANCA: Open Payments
NPI 1528614815 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,493 in 64 payments from 17 companies in 2025. Trend: 2023 $1,550 · 2024 $2,472 · 2025 $1,493
Food & beverage: $1,493
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 13 | $384 |
| Eisai Inc. | 9 | $211 |
| ABBVIE INC. | 7 | $150 |
| Lilly USA, LLC | 8 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $105 |
| Novartis Pharmaceuticals Corporation | 3 | $66 |
| SPR Therapeutics, Inc | 2 | $64 |
| Biogen, Inc. | 3 | $61 |
| TerSera Therapeutics LLC | 2 | $52 |
| Boston Scientific Corporation | 2 | $47 |
Products named: Leqembi, Fintepla, AMYVID, BOTOX, HYQVIA, Briviact, Nayzilam, KESIMPTA.
Industry payments across TX — which companies pay providers there.
